Table 3 Positive and negative predictive values of ctDNA detection at T1 and T4 for pCR (A) and relapse (B).

From: Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer

 

pCR (n)

Non-pCR (n)

PPVa

NPVb

A

T1 (87 variants)

ctDNA+

2

14

88

 

ctDNA−

3

3

 

50

T4 (87 variants)

ctDNA+

2

13

87

 

ctDNA−

5

4

 

56

T1 (TP53 variants)

ctDNA+

2

7

78

 

ctDNA−

1

7

 

13

T4 (TP53 variants)

ctDNA+

1

7

88

 

ctDNA−

3

7

 

30

 

Relapse (n)

Total (n)

PPVa

NPVb

B

T1 (87 variants)

ctDNA+

10

15c

67

 

ctDNA−

1

6

 

83

pCR

1

5

 

80

Non-pCR

10

16c

63

 

T4 (87 variants)

ctDNA+

10

14c

71

 

ctDNA−

1

9

 

89

pCR

1

7

 

86

Non-pCR

10

16c

63

 
  1. ctDNA+, at least 1 variant detected per patient; ctDNA−, no variant detected for any gene.
  2. aPositive predictive value: ability of ctDNA+ to predict non- pCR or relapse.
  3. bNegative predictive value: ability of ctDNA− to predict pCR or freedom from relapse.
  4. cOne patient (Neo-30) was not included in association with relapse since the patient was metastatic.
Back to article page